Ngā hua rapu - Jong‐Mu Sun

Whakamahine hua
  1. 1
    Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherapy

    Significance of Thymidylate Synthase and Thyroid Transcription Factor 1 Expression in Patients with Nonsquamous Non-small Cell Lung Cancer Treated with Pemetrexed-Based Chemotherap... mā Jong‐Mu Sun, Joungho Han, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer

    Prognostic and Predictive Value of KRAS Mutations in Advanced Non-Small Cell Lung Cancer mā Jong‐Mu Sun, Deok Won Hwang, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib

    Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib mā Youjin Kim, Se‐Hoon Lee, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Jong‐Mu Sun

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non–Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either Exon 19 or 21

    Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non–Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor Receptor Mutation in Either... mā Sung Hee Lim, Ji Yun Lee, Jong‐Mu Sun, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer

    Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung Cancer mā Song Ee Park, Se‐Hoon Lee, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Jong‐Mu Sun

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis

    Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis mā Seonggyu Byeon, Jun Soo Ham, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab

    Risk factors for immune-related adverse events associated with anti-PD-1 pembrolizumab mā Yeonghee Eun, In Young Kim, Jong‐Mu Sun, Jeeyun Lee, Hoon‐Suk Cha, Eun‐Mi Koh, Hyungjin Kim, Jaejoon Lee

    I whakaputaina 2019
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC-Positive and FISH-Negative ALK

    A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC-Positive and FISH-Negative ALK mā Jong‐Mu Sun, Yoon‐La Choi, Jae‐Kyung Won, Fred R. Hirsch, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park

    I whakaputaina 2012
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non–Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial

    Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non–Small-Cell Lung Cancer: A Biomarker-Stratified Randomize... mā Jong‐Mu Sun, Jin Seok Ahn, Sin‐Ho Jung, Jiyu Sun, Sang Yun Ha, Joungho Han, Keunchil Park, Myung‐Ju Ahn

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence

    PD‐1 inhibitors for non‐small cell lung cancer patients with special issues: Real‐world evidence mā Seonggyu Byeon, Jang Ho Cho, Hyun Ae Jung, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital

    EGFR Mutation Testing in Patients with Advanced Non-Small Cell Lung Cancer: A Comprehensive Evaluation of Real-World Practice in an East Asian Tertiary Hospital mā Yoon‐La Choi, Jong-Mu Sun, Juhee Cho, Sanjay Rampal, Joungho Han, Bhash Parasuraman, Eliseo Güallar, Genehee Lee, Jeeyun Lee, Young Mog Shim

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer

    Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer mā Bo Mi Ku, Yeon Hee Bae, Kyoung Young Lee, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC

    DNA Damage Response and Repair Pathway Alteration and Its Association With Tumor Mutation Burden and Platinum-Based Chemotherapy in SCLC mā Sehhoon Park, Hayoon Lee, Boram Lee, Se‐Hoon Lee, Jong‐Mu Sun, Woong‐Yang Park, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park

    I whakaputaina 2019
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer

    Real-world data of dacomitinib as first-line treatment for patients with EGFR-mutant non-small-cell lung cancer mā Ji Eun Shin, Hyun Ae Jung, Sehhoon Park, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Myung‐Ju Ahn, Byoung Yong Shim

    I whakaputaina 2025
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication

    Transient Asymptomatic Pulmonary Opacities During Osimertinib Treatment and its Clinical Implication mā Hansang Lee, Ho Yun Lee, Jong‐Mu Sun, Se‐Hoon Lee, Youjin Kim, Song Ee Park, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    Genomic landscape of acquired resistance to third‐generation <i>EGFR</i> tyrosine kinase inhibitors in <i>EGFR</i> T790M‐mutant non–small cell lung cancer

    Genomic landscape of acquired resistance to third‐generation <i>EGFR</i> tyrosine kinase inhibitors in <i>EGFR</i> T790M‐mutant non–small cell lung cancer mā Jiyun Lee, Hong Sook Kim, Boram Lee, Hee Kyung Kim, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park, Se‐Hoon Lee

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma

    The CDK4/6 inhibitor LY2835219 has potent activity in combination with mTOR inhibitor in head and neck squamous cell carcinoma mā Bo Mi Ku, Seong Yoon Yi, Jiae Koh, Yeon-Hee Bae, Jong‐Mu Sun, Se‐Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors

    Leptomeningeal Carcinomatosis in Non–Small-Cell Lung Cancer Patients: Impact on Survival and Correlated Prognostic Factors mā Su Jin Lee, Jung-Il Lee, Do‐Hyun Nam, Young Chan Ahn, Jung Ho Han, Jong‐Mu Sun, Jin Seok Ahn, Keunchil Park, Myung‐Ju Ahn

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma

    High-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma mā Bo Mi Ku, Hyun Ae Jung, Jong‐Mu Sun, Young Hyeh Ko, Han‐Sin Jeong, Young‐Ik Son, Chung‐Hwan Baek, Keunchil Park, Myung‐Ju Ahn

    I whakaputaina 2014
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC

    Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC mā Youjin Kim, Boram Lee, Joonho Shim, Se‐Hoon Lee, Woong‐Yang Park, Yoon‐La Choi, Jong‐Mu Sun, Jin Seok Ahn, Myung‐Ju Ahn, Keunchil Park

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: